BioCryst Pharmaceuticals, Inc. announced that the compensation committee of BioCryst’s board of directors granted 18 newly-hired employees inducement options to purchase an aggregate of 199,000 shares of BioCryst common stock on August 31, 2021 and September 1, 2021 as inducements material to each employee entering into employment with BioCryst.
RESEARCH TRIANGLE PARK, N.C., Sept. 02, 2021 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst’s board of directors granted 18 newly-hired employees inducement options to purchase an aggregate of 199,000 shares of BioCryst common stock on August 31, 2021 and September 1, 2021 as inducements material to each employee entering into employment with BioCryst. The options were granted in accordance with Nasdaq Listing Rule 5635(c)(4).
The options granted on August 31, 2021 have an exercise price of $15.92 per share and the options granted on September 1, 2021 have an exercise price of $16.15 per share, which is equal to the closing price of BioCryst common stock on the respective grant date. The options vest in four equal annual installments beginning on the one-year anniversary of the grant date, in each case subject to the new employee’s continued service with the company. Each stock option has a 10-year term and is subject to the terms and conditions of BioCryst’s Inducement Equity Incentive Plan and a stock option agreement covering the grant.
About BioCryst Pharmaceuticals
BioCryst Pharmaceuticals discovers novel, oral, small-molecule medicines that treat rare diseases in which significant unmet medical needs exist and an enzyme plays a key role in the biological pathway of the disease. Oral, once-daily ORLADEYO® (berotralstat) is approved in the United States, the European Union, Japan and the United Kingdom. BioCryst has several ongoing development programs including BCX9930, an oral Factor D inhibitor for the treatment of complement-mediated diseases, BCX9250, an ALK-2 inhibitor for the treatment of fibrodysplasia ossificans progressiva, and galidesivir, a potential treatment for Marburg virus disease and Yellow Fever. RAPIVAB® (peramivir injection) has received regulatory approval in the U.S., Canada, Australia, Japan, Taiwan and Korea. Post-marketing commitments for RAPIVAB are ongoing. For more information, please visit the company’s website at www.biocryst.com.
BCRXW
Investor Contact:
John Bluth
+1 919 859 7910
jbluth@biocryst.com
Media Contact:
Catherine Collier Kyroulis
+1 917 886 5586
ckyroulis@biocryst.com
